prurigo nodularis and chronic obstructive pulmonary disease. Dupixent is being jointly marketed by Regeneron and Sanofi under ...
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback